Literature DB >> 25929768

Management of advanced-phase chronic myeloid leukemia.

Zachariah DeFilipp1, Hanna Jean Khoury.   

Abstract

The management of chronic myeloid leukemia (CML) in accelerated or blast phase (advanced phase) remains a significant challenge despite the introduction of very effective tyrosine kinase inhibitors (TKIs). The biology of advanced-phase CML is complex and engages several pathways that are not optimally targeted by TKIs. Allogeneic stem cell transplantation remains the only potentially curative therapy, but the effectiveness of this conventional approach is limited. New strategies are required to improve the outlook for these patients.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25929768     DOI： 10.1007/s11899-015-0249-2

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN： 1558-8211            Impact factor:   3.952


  96 in total

1.  Low incidence of transplantation-related acute complications in patients with chronic myeloid leukemia undergoing allogeneic stem cell transplantation with a low-dose (550 cGy) total body irradiation conditioning regimen.

Authors:  H Khoury; D Adkins; R Brown; H Pence; R Vij; L T Goodnough; P Westervelt; K Trinkaus; H S Lin; Y DiPersio
Journal:  Biol Blood Marrow Transplant       Date:  2001       Impact factor: 5.742

2.  Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene.

Authors:  E Shtivelman; B Lifshitz; R P Gale; B A Roe; E Canaani
Journal:  Cell       Date:  1986-10-24       Impact factor: 41.582

3.  Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.

Authors:  R H Collins; O Shpilberg; W R Drobyski; D L Porter; S Giralt; R Champlin; S A Goodman; S N Wolff; W Hu; C Verfaillie; A List; W Dalton; N Ognoskie; A Chetrit; J H Antin; J Nemunaitis
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

4.  Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily.

Authors:  Giuseppe Saglio; Andreas Hochhaus; Yeow Tee Goh; Tamas Masszi; Ricardo Pasquini; Frederic Maloisel; Philipp Erben; Jorge Cortes; Ronald Paquette; M Brigid Bradley-Garelik; Chao Zhu; Herve Dombret
Journal:  Cancer       Date:  2010-08-15       Impact factor: 6.860

5.  High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease.

Authors:  Leo Luznik; Javier Bolaños-Meade; Marianna Zahurak; Allen R Chen; B Douglas Smith; Robert Brodsky; Carol Ann Huff; Ivan Borrello; William Matsui; Jonathan D Powell; Yvette Kasamon; Steven N Goodman; Allan Hess; Hyam I Levitsky; Richard F Ambinder; Richard J Jones; Ephraim J Fuchs
Journal:  Blood       Date:  2010-02-02       Impact factor: 22.113

6.  The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML.

Authors:  Michael E O'Dwyer; Michael J Mauro; Gwen Kurilik; Motomi Mori; Suzanne Balleisen; Susan Olson; Ellen Magenis; Renaud Capdeville; Brian J Druker
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

7.  Peripheral-blood stem cells versus bone marrow from unrelated donors.

Authors:  Claudio Anasetti; Brent R Logan; Stephanie J Lee; Edmund K Waller; Daniel J Weisdorf; John R Wingard; Corey S Cutler; Peter Westervelt; Ann Woolfrey; Stephen Couban; Gerhard Ehninger; Laura Johnston; Richard T Maziarz; Michael A Pulsipher; David L Porter; Shin Mineishi; John M McCarty; Shakila P Khan; Paolo Anderlini; William I Bensinger; Susan F Leitman; Scott D Rowley; Christopher Bredeson; Shelly L Carter; Mary M Horowitz; Dennis L Confer
Journal:  N Engl J Med       Date:  2012-10-18       Impact factor: 91.245

8.  Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose.

Authors:  Cesare Guglielmi; William Arcese; Francesco Dazzi; Ronald Brand; Donald Bunjes; Leo F Verdonck; Anton Schattenberg; Hans-Jochem Kolb; Per Ljungman; Agnes Devergie; Andrea Bacigalupo; Marta Gomez; Mauricette Michallet; Ahmet Elmaagacli; Alois Gratwohl; Jane Apperley; Dietger Niederwieser
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

9.  Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.

Authors:  H Jean Khoury; Jorge E Cortes; Hagop M Kantarjian; Carlo Gambacorti-Passerini; Michele Baccarani; Dong-Wook Kim; Andrey Zaritskey; Athena Countouriotis; Nadine Besson; Eric Leip; Virginia Kelly; Tim H Brümmendorf
Journal:  Blood       Date:  2012-02-27       Impact factor: 22.113

10.  Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

Authors:  Giuseppe Saglio; Dong-Wook Kim; Surapol Issaragrisil; Philipp le Coutre; Gabriel Etienne; Clarisse Lobo; Ricardo Pasquini; Richard E Clark; Andreas Hochhaus; Timothy P Hughes; Neil Gallagher; Albert Hoenekopp; Mei Dong; Ariful Haque; Richard A Larson; Hagop M Kantarjian
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245
View more
  2 in total

1.  Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias.

Authors:  Abhishek Maiti; Miguel J Franquiz; Farhad Ravandi; Jorge E Cortes; Elias J Jabbour; Koji Sasaki; Kayleigh Marx; Naval G Daver; Tapan M Kadia; Marina Y Konopleva; Lucia Masarova; Gautam Borthakur; Courtney D DiNardo; Kiran Naqvi; Sherry Pierce; Hagop M Kantarjian; Nicholas J Short
Journal:  Acta Haematol       Date:  2020-04-14       Impact factor: 2.195

Review 2.  Efficacy of Dasatinib in a CML Patient in Blast Crisis with F317L Mutation: A Case Report and Literature Review.

Authors:  E V Morozova; Y Y Vlasova; M V Pryanishnikova; K V Lepik; B V Afanasyev
Journal:  Biomark Insights       Date:  2015-12-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.